Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn’s Disease: A Systematic Review
Sign Up to like & getrecommendations! Published in 2019 at "Digestive Diseases and Sciences"
DOI: 10.1007/s10620-019-05635-1
Abstract: Tumor necrosis factor (TNF) antagonists are considered the cornerstone therapy for fistulizing perianal Crohn’s disease (PCD), yet a substantial proportion of patients fail to achieve healing. Therefore, we reviewed the evidence for strategies to enhance… read more here.
Keywords: tnf; fistula healing; anti tnf; tumor necrosis ... See more keywords
P606 Use of TNF-α-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab232.732
Abstract: Patients with Inflammatory Bowel Disease (IBD) frequently use immunomodulating treatment, which may render them at increased risk of attenuated immunogenicity after vaccination. Immunosuppressive drugs, such as TNF-α-antagonists, have shown an attenuating effect on serological response… read more here.
Keywords: systemic steroids; sars cov; vaccination; antibody ... See more keywords
The therapeutic potential of TNF‐α antagonists in toxic epidermal necrosis: insights from two cases and adverse event reports
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.15006
Abstract: Treatment of toxic epidermal necrolysis (TEN) represents a significant challenge for the clinicians. Several recent reports proposed that inhibition of tumour necrosis factor alfa (TNF-α) may improve the prognosis of TEN1-5 . A recent study… read more here.
Keywords: necrosis; potential tnf; tnf; tnf antagonists ... See more keywords
SAT0046 TNF antagonist drug safety assessment by pharmacovigilance signaling and post-marketing adverse event reports
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.5884
Abstract: Background TNF antagonists have been equally effective in the treatment of immunoinflammatory diseases. However, differences in their characteristics and the introduction of biosimilars may be associated with different safety profiles. Objectives The main goal of… read more here.
Keywords: ifx; safety; database; adverse events ... See more keywords
Microsporidia Infection in Patients with Autoimmune Diseases.
Sign Up to like & getrecommendations! Published in 2020 at "Indian journal of medical microbiology"
DOI: 10.4103/ijmm.ijmm_20_325
Abstract: PURPOSE Microsporidium is a spore-forming intracellular parasite that affects a wide range of hosts including humans. The tumor necrosis factor alpha (TNF-α) plays a key role in the immunity to infection with microsporidia. Recently, the… read more here.
Keywords: infection; tnf antagonists; microsporidia infection; group ... See more keywords
Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Dermatology"
DOI: 10.5021/ad.2019.31.5.495
Abstract: Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high… read more here.
Keywords: antagonists psoriasis; tumor necrosis; psoriasis; tnf antagonists ... See more keywords